Benign Growth For Applied DNA Sciences, Inc. (NASDAQ:APDN) Underpins Stock's 27% Plummet
Benign Growth For Applied DNA Sciences, Inc. (NASDAQ:APDN) Underpins Stock's 27% Plummet
Unfortunately for some shareholders, the Applied DNA Sciences, Inc. (NASDAQ:APDN) share price has dived 27% in the last thirty days, prolonging recent pain. For any long-term shareholders, the last month ends a year to forget by locking in a 57% share price decline.
不幸的是，对于一些股东来说，应用DNA科学公司。纳斯达克(新浪纳斯达克：APDN)股价在过去30天里暴跌27%，延续了最近的痛苦。对于任何长期股东来说，最后一个月以锁定股价下跌57%的方式结束了一年的忘记。
Following the heavy fall in price, Applied DNA Sciences' price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now compared to the wider Life Sciences industry in the United States, where around half of the companies have P/S ratios above 3.3x and even P/S above 7x are quite common. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.
随着股价的大幅下跌，应用DNA科学公司0.9倍的市售比(P/S)可能会让它看起来像是一个强劲的买入对象。在美国，大约一半的公司的P/S比率高于3.3倍，甚至P/S高于7倍的情况也很常见。然而，仅仅从表面上看待P/S是不明智的，因为可能会有一个解释为什么它如此有限。
View our latest analysis for Applied DNA Sciences
查看我们对应用DNA科学的最新分析
How Has Applied DNA Sciences Performed Recently?
应用DNA科学最近表现如何？
While the industry has experienced revenue growth lately, Applied DNA Sciences' revenue has gone into reverse gear, which is not great. The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.
虽然该行业最近经历了收入增长，但应用DNA科学的收入却出现了逆转，这并不是很好。市盈率与S的比率之所以偏低，可能是因为投资者认为这种糟糕的营收表现不会好转。如果是这样的话，现有股东很可能很难对股价的未来走势感到兴奋。
How Is Applied DNA Sciences' Revenue Growth Trending?
应用DNA科学的收入增长趋势如何？
Applied DNA Sciences' P/S ratio would be typical for a company that's expected to deliver very poor growth or even falling revenue, and importantly, perform much worse than the industry.
对于一家预计增长非常缓慢，甚至收入下降，更重要的是，表现远逊于行业的公司来说，应用DNA科学的P/S比率是典型的。
In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 8.5%. Spectacularly, three year revenue growth has ballooned by several orders of magnitude, despite the drawbacks experienced in the last 12 months. So while the company has done a great job in the past, it's somewhat concerning to see revenue growth decline so harshly.
回顾过去一年的财务状况，我们沮丧地看到该公司的收入下降到了8.5%。令人惊叹的是，尽管过去12个月经历了一些不利因素，但三年的收入增长却激增了几个数量级。因此，尽管该公司过去做得很好，但看到收入增长如此严重地下滑，有些令人担忧。
Looking ahead now, revenue is anticipated to slump, contracting by 29% during the coming year according to the two analysts following the company. Meanwhile, the broader industry is forecast to expand by 0.7%, which paints a poor picture.
根据跟踪该公司的两位分析师的说法，展望未来，收入预计将大幅下滑，来年将收缩29%。与此同时，更广泛的行业预计将增长0.7%，这描绘了一幅糟糕的图景。
With this in consideration, we find it intriguing that Applied DNA Sciences' P/S is closely matching its industry peers. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.
考虑到这一点，我们发现耐人寻味的是，应用DNA科学的P/S与其行业同行不相上下。然而，营收缩水不太可能带来长期稳定的市盈率/S。如果该公司不改善其营收增长，市盈率S有可能跌至更低的水平。
What Does Applied DNA Sciences' P/S Mean For Investors?
应用DNA科学的P/S对投资者意味着什么？
Applied DNA Sciences' P/S looks about as weak as its stock price lately. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.
应用DNA科学公司的P/S最近看起来和它的股价一样疲软。一般来说，我们倾向于将市销率的使用限制在确定市场对公司整体健康状况的看法上。
It's clear to see that Applied DNA Sciences maintains its low P/S on the weakness of its forecast for sliding revenue, as expected. As other companies in the industry are forecasting revenue growth, Applied DNA Sciences' poor outlook justifies its low P/S ratio. It's hard to see the share price rising strongly in the near future under these circumstances.
很明显，正如预期的那样，应用DNA科学维持其较低的市盈率S，原因是其对营收下滑的预测疲软。就在业内其他公司都在预测营收增长之际，应用DNA科学的糟糕前景证明其低市盈率是合理的。在这种情况下，很难看到股价在不久的将来强劲上涨。
It's always necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Applied DNA Sciences (at least 1 which shouldn't be ignored), and understanding these should be part of your investment process.
总是有必要考虑到投资风险的幽灵无处不在。我们已经确定了应用DNA科学公司的5个警告信号(至少有一个不应该被忽视)，理解这些应该是你投资过程的一部分。
It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).
重要的是确保你寻找的是一家伟大的公司，而不仅仅是你遇到的第一个想法。因此，如果不断增长的盈利能力符合你对一家伟大公司的看法，不妨看看这一点免费近期收益增长强劲(市盈率较低)的有趣公司名单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗？担心内容吗？ 保持联系直接与我们联系。或者，也可以给编辑组发电子邮件，地址是implywallst.com。
本文由Simply Wall St.撰写，具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论，我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议，也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意，我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。